Request Demo
Last update 25 Apr 2026
SXC-2023
Last update 25 Apr 2026
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms SXC 2023 |
Target |
Action stimulants |
Mechanism SLC7A11 stimulants(Cystine/glutamate transporter stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Molecular FormulaC15H19NO4S |
InChIKeyWSPBIYTZXPCLCG-ZDUSSCGKSA-N |
CAS Registry1695562-35-6 |
Related
5
Clinical Trials associated with SXC-2023NCT06343532
Phase 1, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess Potential Interactions Between Intravenous Cocaine and Oral SXC-2023
NCT03887429
An Exploratory, Placebo-Controlled, Crossover Study to Examine the Safety and Activity of SXC-2023 to Improve Behavioral Dynamics in Non-Treatment Seeking Adults Undergoing Acute Nicotine Withdrawal
NCT03797521
A Phase 2, Double Blind, Placebo-Controlled Study to Explore the Safety, Tolerability, and Activity of SXC-2023 in Adults With Moderate to Severe Trichotillomania (TTM) When Dosed for 6 Weeks
100 Clinical Results associated with SXC-2023
Login to view more data
100 Translational Medicine associated with SXC-2023
Login to view more data
100 Patents (Medical) associated with SXC-2023
Login to view more data
100 Deals associated with SXC-2023
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Disruptive, Impulse Control, and Conduct Disorders | Phase 2 | United States | 04 Mar 2019 | |
| Trichotillomania | Phase 2 | United States | 19 Dec 2018 | |
| Cocaine-Related Disorders | Phase 1 | United States | 08 Oct 2024 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 2 | 34 | (During 200 mg SXC-2023 Treatment) | piowhxbdtn = mykcoyxmde gghzmxcfsx (uiqjvmatlo, glrpxmhqlh - kjxbfrdccp) View more | - | 17 Jul 2020 | ||
(During 800 mg SXC-2023 Treatment) | piowhxbdtn = ijykjfmxhd gghzmxcfsx (uiqjvmatlo, bthteqvqyl - wvhmosdmht) View more | ||||||
Phase 1 | - | 48 | (SXC-2023, 50 mg) | rfepbhriuk = lylekgjlne kngtmdwedk (qlbfcschgr, kvnuayexjg - ldxkmappuf) View more | - | 26 Sep 2019 | |
(SXC-2023, 100 mg) | rfepbhriuk = gxfrczscno kngtmdwedk (qlbfcschgr, znqqouxcnh - bmvhshdumh) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free